Newcardio, Inc. (NWCI)

[califax]

NewCardio awarded core patent concerning its CardioBip ECG telemonitoring solution

17. Januar 2010 23:57 - THE MEDICAL NEWS
http://www.news-medical.net/news/20100117/NewCardio-awarded-core-patent-concerning-its-CardioBip-ECG-telemonitoring-solution.aspx

NewCardio, Inc., (OTC Bulletin Board: NWCI) a cardiac diagnostic technology provider, announced today that on January 12, 2010, it received notice of allowance for U.S. patent 7,647,093, titled "Apparatus and method for cordless recording and telecommunication transmission of three special ECG leads and their processing," from the U.S. Patent and Trademark Office. This represents the core patent for CardioBip™ and, in conjunction with the two encouraging validation studies announced on January 5, 2010, validates the CardioBip technology, positioning NewCardio as an emerging leader in remote cardiac monitoring.

The CardioBip is a unique, hand-held device that provides a solution for ECG telemonitoring. Patients can carry the CardioBip with them and use it to generate and transmit synthesized, accurate 12-lead ECGs at physician prescribed intervals of time, during ordinary daily activity or when symptoms develop. What makes CardioBip unique is its extreme ease of use, combined with the ability to generate recordings substantially equivalent in quality with standard 12-lead ECGs. The CardioBip works without any cables, cumbersome leads, wires or inconvenient skin electrodes, as the device's electrodes are integrated, offering potential compatibility with popular hand-held PDA platforms.

Branislav Vajdic, Ph.D., chief executive officer of NewCardio, Inc., commented, "This patent strengthens our intellectual property protection creating a significant barrier to entry for a competing device. We believe the CardioBip technology fills an important technological and diagnostic void, enabling not only rhythm diagnosis, but also detection of ischemic ECG changes and precise reconstruction of atrial activity. At present there is no convenient and reliable method for remote monitoring and detection of either ischemic events or derangements of atrial electrical activity, but this patent and the two recently completed validation studies indicate that the CardioBip may potentially fill this need. This patent protects the core technology underlying the CardioBip. The patent comes immediately following the encouraging results from two validation studies, which confirmed CardioBip's ability to record, reconstruct and transmit an accurate, high-resolution 12-lead ECG. NewCardio is committed to advancing the widely accepted 12-lead ECG to deliver innovation to the cardiac sciences. We are gratified by the U.S. Patent and Trademark Office's grant of patent rights and pleased that they approved all 33 claims."

Dorin Panescu, Ph.D., NewCardio's Chief Technical Officer and Vice-President of Research and Development, added, "NewCardio remains committed to an aggressive and comprehensive intellectual property (IP) strategy. The Company's IP portfolio evenly covers innovation and invention for all three of our solutions: QTinno™, CardioBip and Visual3Dx™. The patent issued today stresses the importance NewCardio places on patient-friendly, effective and accurate remote wireless patient monitoring, an important, emerging and under-served segment of health care."
SOURCE NewCardio, Inc.